Xanthohumol inhibits notch signaling and induces apoptosis in hepatocellular carcinoma

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Kunnimalaiyaan, Selvi ^a   Sokolowski, Kevin M ^a   Balamurugan, Mariappan ^a   Gamblin, T Clark ^a   Kunnimalaiyaan, Muthusamy ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CYCLIN D1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOTCH RECEPTOR; PROTEIN MCL 1; SURVIVIN; TRANSCRIPTION FACTOR HES 1; XANTHOHUMOL; FLAVONOID; PROPIOPHENONE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMING CELL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; METASTASIS POTENTIAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL SURVIVAL; DRUG EFFECTS; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLAVONOIDS; HUMANS; LIVER NEOPLASMS; PROPIOPHENONES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY;

EID: 84949649299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127464     Document Type: Article

References (41)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nature reviews Gastroenterology & hepatology. 2010; 7(8):448-58. doi: 10.1038/nrgastro.2010.100 PMID: 20628345; PubMed Central PMCID: PMC3926946.
2. Worns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. Journal of clinical gastroenterology. 2009; 43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6 PMID: 19247201.
3. Worns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstatter T, et al. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2013; 45(5):408-13. doi: 10. 1016/j.dld.2012.10.010 PMID: 23182599.
4. Worns MA, Klockner R, Weinmann A, Galle PR. [Therapy of hepatocellular carcinoma]. Der Internist. 2014; 55(1):23-4, 6-30. doi: 10.1007/s00108-013-3318-4 PMID: 24240604.
5. Worns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert opinion on investigational drugs. 2010; 19(5):615-29. doi: 10.1517/13543781003767418 PMID: 20374038.
6. Zhou L, Zhang N, Song W, You N, Li Q, Sun W, et al. The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma. PloS one. 2013; 8(2):e57382. doi: 10.1371/journal.pone.0057382 PMID: 23468978; PubMed Central PMCID: PMC3585338.
7. Gao J, Song Z, Chen Y, Xia L, Wang J, Fan R, et al. Deregulated expression of Notch receptors in human hepatocellular carcinoma. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2008; 40(2):114-21. doi: 10. 1016/j.dld.2007.08.001 PMID: 17920003.
8. Ahn S, Hyeon J, Park CK. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary & pancreatic diseases international: HBPD INT. 2013; 12(3):286-94. PMID: 23742774.
9. Zhang S, Yang Y, Liang Z, Duan W, Yang J, Yan J, et al. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells. PloS one. 2013; 8(12):e83699. doi: 10.1371/journal.pone.0083699 PMID: 24386256; PubMed Central PMCID: PMC3873967.
10. Wang XQ, Zhang W, Lui EL, Zhu Y, Lu P, Yu X, et al. Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. International journal of cancer Journal international du cancer. 2012; 131(3): E163-72. doi: 10.1002/ijc.27336 PMID: 22052196.
11. Sun Q, Wang R, Wang Y, Luo J, Wang P, Cheng B. Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-Associated hepatocellular carcinoma. Oncol Rep. 2014; 31 (2):933-9. doi: 10.3892/or.2013.2917 PMID: 24336972.
12. Sun Q, Wang R, Luo J, Wang P, Xiong S, Liu M, et al. Notch1 promotes hepatitis B virus X protein-induced hepatocarcinogenesis via Wnt/beta-catenin pathway. International journal of oncology. 2014; 45 (4):1638-48. doi: 10.3892/ijo.2014.2537 PMID: 25017705.
13. Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer research. 2007; 67(5):1879-82. doi: 10.1158/0008-5472.CAN-06-3958 PMID: 17332312.
14. Zhou L, Wang DS, Li QJ, Sun W, Zhang Y, Dou KF. The down-regulation of Notch1 inhibits the invasion and migration of hepatocellular carcinoma cells by inactivating the cyclooxygenase-2/Snail/E-cadherin pathway in vitro. Digestive diseases and sciences. 2013; 58(4):1016-25. doi: 10.1007/s10620-012-2434-7 PMID: 23053901.
15. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010; 464(7291):1052-7. doi: 10.1038/nature08878 PMID: 20393564.
16. Moellering RE, Cornejo M, Davis TN, Del BC, Aster JC, Blacklow SC, et al. Direct inhibition of the NOTCH transcription factor complex. Nature. 2009; 462(7270):182-8. doi: 10.1038/nature08543 PMID: 19907488
17. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacology & therapeutics. 2013; 139 (2):95-110. doi: 10.1016/j.pharmthera.2013.02.003 PMID: 23458608; PubMed Central PMCID: PMC3732476.
18. Kim SY, Lee IS, Moon A. 2-Hydroxychalcone and xanthohumol inhibit invasion of triple negative breast cancer cells. Chemico-biological interactions. 2013; 203(3):565-72. doi: 10.1016/j.cbi.2013.03.012 PMID: 23562496.
19. Kang Y, Park MA, Heo SW, Park SY, Kang KW, Park PH, et al. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. Biochimica et biophysica acta. 2013; 1830(3):2638-48. doi: 10.1016/j.bbagen.2012.12. 005 PMID: 23246576.
20. Monteiro R, Calhau C, Silva AO, Pinheiro-Silva S, Guerreiro S, Gartner F, et al. Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. Journal of cellular biochemistry. 2008; 104(5):1699-707. doi: 10.1002/jcb.21738 PMID: 18348194.
21. Pan L, Becker H, Gerhauser C. Xanthohumol induces apoptosis in cultured 40-16 human colon cancer cells by activation of the death receptor-And mitochondrial pathway. Molecular nutrition & food research. 2005; 49(9):837-43. doi: 10.1002/mnfr.200500065 PMID: 15995977.
22. Dorn C, Weiss TS, Heilmann J, Hellerbrand C. Xanthohumol, a prenylated chalcone derived from hops, inhibits proliferation, migration and interleukin-8 expression of hepatocellular carcinoma cells. International journal of oncology. 2010; 36(2):435-41. PMID: 20043079.
23. Cook MR, Luo J, Ndiaye M, Chen H, Kunnimalaiyaan M. Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer. American journal of surgery. 2010; 199(3):315-8; discussion 8. doi: 10.1016/j.amjsurg.2009.08.034 PMID: 20226902; PubMed Central PMCID: PMC2841322.
24. Drenzek JG, Seiler NL, Jaskula-Sztul R, Rausch MM, Rose SL. Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines. Gynecologic oncology. 2011; 122(2):396-401. doi: 10.1016/j.ygyno.2011.04.027 PMID: 21616523.
25. Gerhauser C, Alt A, Heiss E, Gamal-Eldeen A, Klimo K, Knauft J, et al. Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. Molecular cancer therapeutics. 2002; 1 (11):959-69. PMID: 12481418.
26. Vene R, Benelli R, Minghelli S, Astigiano S, Tosetti F, Ferrari N. Xanthohumol impairs human prostate cancer cell growth and invasion and diminishes the incidence and progression of advanced tumors in TRAMP mice. Molecular medicine. 2012; 18:1292-302. doi: 10.2119/molmed.2012.00174 PMID: 22952060; PubMed Central PMCID: PMC3521786.
27. Deeb D, Gao X, Jiang H, Arbab AS, Dulchavsky SA, Gautam SC. Growth inhibitory and apoptosis-inducing effects of xanthohumol, a prenylated chalone present in hops, in human prostate cancer cells. Anticancer research. 2010; 30(9):3333-9. PMID: 20944105.
28. Zajc I, Filipic M, Lah TT. Xanthohumol induces different cytotoxicity and apoptotic pathways in malignant and normal astrocytes. Phytotherapy research: PTR. 2012; 26(11):1709-13. doi: 10.1002/ptr. 4636 PMID: 22407755.
29. Yang M, Li N, Li F, Zhu Q, Liu X, Han Q, et al. Xanthohumol, a main prenylated chalcone from hops, reduces liver damage and modulates oxidative reaction and apoptosis in hepatitis C virus infected Tupaia belangeri. International immunopharmacology. 2013; 16(4):466-74. doi: 10.1016/j.intimp.2013.04.029 PMID: 23669332.
30. Delmulle L, Vanden Berghe T, De Keukeleire D, Vandenabeele P. Treatment of PC-3 and DU145 prostate cancer cells by prenylflavonoids from hop (Humulus lupulus L.) induces a caspase-independent form of cell death. Phytother Res. 2008; 22(2):197-203. doi: 10.1002/Ptr.2286 PMID: WOS:000254229000010.
31. Vanhoecke BW, Delporte F, Van Braeckel E, Heyerick A, Depypere HT, Nuytinck M, et al. A safety study of oral tangeretin and xanthohumol administration to laboratory mice. In vivo. 2005; 19(1):103-7. PMID: 15796161.
32. Hussong R, Frank N, Knauft J, Ittrich C, Owen R, Becker H, et al. A safety study of oral xanthohumol administration and its influence on fertility in Sprague Dawley rats. Molecular nutrition & food research. 2005; 49(9):861-7. doi: 10.1002/mnfr.200500089 PMID: 16092070.
33. Hanske L, Hussong R, Frank N, Gerhauser C, Blaut M, Braune A. Xanthohumol does not affect the composition of rat intestinal microbiota. Molecular nutrition & food research. 2005; 49(9):868-73. doi: 10.1002/mnfr.200500048 PMID: 16092067.
34. Carter YM, Kunnimalaiyaan S, Chen H, Gamblin TC, Kunnimalaiyaan M. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer biology & therapy. 2014; 15(5):510-5. doi: 10.4161/cbt.28015 PMID: 24521712; PubMed Central PMCID: PMC4026073.
35. Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, et al. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer letters. 2013; 335(1):41-51. doi: 10.1016/j.canlet.2013.01.054 PMID: 23402814; PubMed Central PMCID: PMC3665739.
36. Vanhoecke B, Derycke L, Van Marck V, Depypere H, De Keukeleire D, Bracke M. Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. International journal of cancer Journal international du cancer. 2005; 117(6):889-95. doi: 10.1002/ijc.21249 PMID: 15986430.
37. Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M, Offner F. Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Molecular nutrition & food research. 2005; 49(9):844-50. doi: 10.1002/mnfr.200500045 PMID: 16144030.
38. Naganuma S, Whelan KA, Natsuizaka M, Kagawa S, Kinugasa H, Chang S, et al. Notch receptor inhibition reveals the importance of cyclin D1 and Wnt signaling in invasive esophageal squamous cell carcinoma. American journal of cancer research. 2012; 2(4):459-75. PMID: 22860235; PubMed Central PMCID: PMC3410579.
39. Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB, et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer research. 2009; 69(2):573-82. doi: 10.1158/0008-5472 CAN-08-2088. PMID: 19147571; PubMed Central PMCID: PMC3242515.
40. Chen Y, Li D, Liu H, Xu H, Zheng H, Qian F, et al. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer biology & therapy. 2011; 11(1):14-21. PMID: 20962575.
41. Legette L, Karnpracha C, Reed RL, Choi J, Bobe G, Christensen JM, et al. Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops. Molecular nutrition & food research. 2014; 58 (2):248-55. doi: 10.1002/mnfr.201300333 PMID: 24038952.